Mobility is the key to corneal surgery

Article

Ziemer has launched a new corneal surgery model to expand the capabilities of its LDV Femtosecond laser system.

Ziemer has launched a new corneal surgery model to expand the capabilities of its LDV Femtosecond laser system.

The LDV system has been in the market for the last two years and according to Anton Wirthlin, vice president of marketing and corporate communications, has been very successful, with Ziemer selling 150 systems worldwide and treating more than 200,000 eyes.

“Word has got out. We have earned a reputation as a high-tech flap maker delivering perfect incisions. Doctors are reporting very positive outcomes, with strong-short term results leading to patients going away happy and making subsequent referrals.”

Ziemer hopes to match this clinical success with the mobility of the LDV system to expand doctor’s capabilities in the corneal surgery market.

Although Femtosecond lasers have been in routine use in refractive surgery for several years, the bulk of and inflexibility of the equipment is perceived as an obstacle to more widespread use in corneal applications.

According to Wirthlin, Ziemer's Femto LDV system is the only femtosecond laser that is compact and mobile enough to really facilitate both refractive and corneal usage. “A laser can't really do both LASIK and corneal surgery if it is stationary. It will be capable of doing both, but it's not practical if it can't be moved around.“

Ziemer's new corneal surgery module enables surgeons to perform tunnel incisions for intracorneal rings, pocket incisions for intrastromnal inlays corneal inlays and lamellar keratoplasty.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.